Search

Displaying results 571 - 580 of 595 in total
  1. Drug

    Droloxifene

    go.drugbank.com/drugs/DB15641
    Experimental

    receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity give it theoretical advantages over

  2. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    application within six months of application filing where the agency determines that the drug if approved, would provide a significant improvement in treating, diagnosing or preventing a serious condition over

  3. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Gantenerumab binds to a unique Aβ epitope compared to other anti-Aβ antibodies and preferentially recognizes Aβ oligomers and fibrils over monomers.[A244720]

  4. Drug

    Carbon monoxide

    go.drugbank.com/drugs/DB11588
    ApprovedInvestigational

    There have been several concerns voiced of over the use of carbon monoxide in food products [L2537], [L2538], [L2539].

  5. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    [A18262] Use of non-stimulant medications such as atomoxetine is therefore thought to offer a clinical advantage over the use of traditional medications for the management of ADHD.

  6. Drug

    Esomeprazole

    go.drugbank.com/drugs/DB00736
    ApprovedInvestigational

    [A177577, A177580] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread.

  7. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon-based regimens, which were limited by infusion site reactions, reduced blood count, and

  8. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon- and ribavirin-based regimens, which were limited by infusion site reactions, reduced blood

  9. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon- and ribavirin-based regimens, which were limited by infusion site reactions, reduced blood

  10. Drug

    ADH-1

    go.drugbank.com/drugs/DB05485
    Investigational

    Poorly differentiated, highly invasive carcinomas are characterized by over-expression of N-cadherin (as opposed to E-cadherin).